BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) today reported data from a phase I clinical trial of SGN-35 administered every three weeks to patients with Hodgkin lymphoma and other CD30-positive hematologic malignancies. Data highlights include longer median duration of response than previously reported and concordance between investigator-assessed and independent review of responses. The data were presented at the 14th Congress of the European Hematology Association (EHA) being held in Berlin, Germany.
